Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS mutant |
Therapy | LTT462 + LXH 254 |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS mutant | melanoma | predicted - sensitive | LTT462 + LXH 254 | Phase II | Actionable | In a Phase II trial, combination treatment with LXH 254 and LTT462 demonstrated tolerable safety in patients with NRAS-mutant melanoma, and led to a disease control rate of 62% (18/29), with a confirmed partial response in 6 patients and stable disease in 12 patients (Ann Oncol (2022) 33 (suppl_7): S197-S224; NCT04417621). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma | Full reference... |